Biomarkers, Diagnostics, Monitoring, Cancer, Autoimmune diseases, Inflammation, Protein-protein interactions, Post-translational modifications
The comany has developed QF-Pro, a technology that makes it possible to quantify – with very high accuracy – a whole new family of biomarkers for pathological anatomy: the population of protein complexes formed and the population of proteins that have undergone post-translational modification in patient tissue samples. The company’s goal is to open new avenues for developing more effective treatments and diagnostics for a multitude of pathologies, including cancer, infectious and immune diseases, and inflammation. The company works with its customers to develop ad-hoc assays to improve their competitiveness, the initial focus being the development of an immuno-oncology assay that makes it possible to directly quantify complexes of PD-1/PD-L1 immune checkpoints that have formed in patients’ biopsies.
DESCRIPTION
The has developed QF-Pro, a technology that makes it possible to quantify – with very high accuracy – a whole new family of biomarkers for pathological anatomy: the population of protein complexes formed and the population of proteins that have undergone post-translational modification in patient tissue samples. The company’s goal is to open new avenues for developing more effective treatments and diagnostics for a multitude of pathologies, including cancer, infectious and immune diseases, and inflammation. The company works with its customers to develop ad-hoc assays to improve their competitiveness, the initial focus being the development of an immuno-oncology assay that makes it possible to directly quantify complexes of PD-1/PD-L1 immune checkpoints that have formed in patients’ biopsies.
Keywords
Biomarkers, Diagnostics, Monitoring, Cancer, Autoimmune diseases, Inflammation, Protein-protein interactions, Post-translational modifications.
